Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 2.78
NAS:BIVV's Cash-to-Debt is ranked higher than
61% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:BIVV: 2.78 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:BIVV' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.78  Med: 5001.39 Max: No Debt
Current: 2.78
Equity-to-Asset 0.50
NAS:BIVV's Equity-to-Asset is ranked higher than
56% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:BIVV: 0.50 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:BIVV' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.5  Med: 0.74 Max: 0.81
Current: 0.5
0.5
0.81
Debt-to-Equity 0.07
NAS:BIVV's Debt-to-Equity is ranked lower than
99.99% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:BIVV: 0.07 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:BIVV' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07  Med: 0.07 Max: 0.07
Current: 0.07
Interest Coverage No Debt
NAS:BIVV's Interest Coverage is ranked lower than
52% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:BIVV: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:BIVV' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 7.28
Beneish M-Score: -0.32
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 37.65
NAS:BIVV's Operating Margin % is ranked higher than
94% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:BIVV: 37.65 )
Ranked among companies with meaningful Operating Margin % only.
NAS:BIVV' s Operating Margin % Range Over the Past 10 Years
Min: -267.93  Med: 17.49 Max: 37.65
Current: 37.65
-267.93
37.65
Net Margin % 44.10
NAS:BIVV's Net Margin % is ranked higher than
96% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:BIVV: 44.10 )
Ranked among companies with meaningful Net Margin % only.
NAS:BIVV' s Net Margin % Range Over the Past 10 Years
Min: -268.08  Med: 19.38 Max: 49.54
Current: 44.1
-268.08
49.54
ROE % 86.91
NAS:BIVV's ROE % is ranked higher than
99% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:BIVV: 86.91 )
Ranked among companies with meaningful ROE % only.
NAS:BIVV' s ROE % Range Over the Past 10 Years
Min: -245.27  Med: 32.01 Max: 92.46
Current: 86.91
-245.27
92.46
ROA % 57.43
NAS:BIVV's ROA % is ranked higher than
99% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:BIVV: 57.43 )
Ranked among companies with meaningful ROA % only.
NAS:BIVV' s ROA % Range Over the Past 10 Years
Min: -191.45  Med: 25.49 Max: 72.81
Current: 57.43
-191.45
72.81
ROC (Joel Greenblatt) % 127.48
NAS:BIVV's ROC (Joel Greenblatt) % is ranked higher than
94% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:BIVV: 127.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:BIVV' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -274.99  Med: 31.23 Max: 127.48
Current: 127.48
-274.99
127.48
GuruFocus has detected 3 Warning Signs with Bioverativ Inc $NAS:BIVV.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:BIVV's 30-Y Financials

Financials (Next Earnings Date: 2017-11-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

BIVV Guru Trades in

Q4 2016

BIVV Guru Trades in Q4 2016

John Burbank 2,952 sh (unchged)
Frank Sands 1,289,455 sh (unchged)
Eric Mindich 163,941 sh (unchged)
Ronald Muhlenkamp 11,640 sh (unchged)
Mairs and Power 513 sh (unchged)
Richard Snow 96,181 sh (unchged)
John Paulson 26,100 sh (unchged)
HOTCHKIS & WILEY 143,400 sh (unchged)
Joel Greenblatt 120,156 sh (unchged)
First Eagle Investment 128,513 sh (unchged)
Ron Baron 3,313 sh (unchged)
David Dreman 301 sh (unchged)
Ken Fisher 50,944 sh (unchged)
Mario Gabelli 936 sh (unchged)
Murray Stahl 3,328 sh (unchged)
John Buckingham 8,467 sh (unchged)
Jim Simons 353,748 sh (unchged)
Paul Tudor Jones 3,908 sh (unchged)
Steven Cohen 26,771 sh (unchged)
Jeff Auxier 12,653 sh (unchged)
Lee Ainslie 5,440 sh (unchged)
Andreas Halvorsen 959,406 sh (unchged)
John Hussman 175 sh (unchged)
PRIMECAP Management 7,792,194 sh (unchged)
Vanguard Health Care Fund 1,920,902 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 83,250 sh (unchged)
» More
Q1 2017

BIVV Guru Trades in Q1 2017

Columbia Wanger 473,000 sh (New)
Jeff Ubben 8,476,892 sh (New)
Paul Tudor Jones 705,824 sh (+17961.00%)
Jeff Auxier 24,179 sh (+91.09%)
First Eagle Investment 157,035 sh (+22.19%)
Lee Ainslie Sold Out
Jim Simons Sold Out
Mairs and Power Sold Out
Steven Cohen Sold Out
Andreas Halvorsen Sold Out
John Hussman Sold Out
Frank Sands Sold Out
Eric Mindich Sold Out
John Buckingham Sold Out
Mario Gabelli Sold Out
David Dreman Sold Out
John Burbank Sold Out
Ron Baron Sold Out
HOTCHKIS & WILEY Sold Out
Vanguard Health Care Fund Sold Out
John Paulson Sold Out
Ken Fisher Sold Out
Murray Stahl Sold Out
PRIMECAP Management 7,741,094 sh (-0.66%)
Ronald Muhlenkamp 11,543 sh (-0.83%)
Joel Greenblatt 109,907 sh (-8.53%)
Richard Snow 13,850 sh (-85.60%)
Eaton Vance Worldwide Health Sciences Fund 77,284 sh (-7.17%)
» More
Q2 2017

BIVV Guru Trades in Q2 2017

Louis Moore Bacon 25,000 sh (New)
Joel Greenblatt 227,377 sh (+106.88%)
Columbia Wanger 589,054 sh (+24.54%)
Eaton Vance Worldwide Health Sciences Fund 134,621 sh (+74.19%)
Jeff Auxier 24,179 sh (unchged)
First Eagle Investment Sold Out
Richard Snow Sold Out
Paul Tudor Jones Sold Out
Ronald Muhlenkamp 11,531 sh (-0.10%)
PRIMECAP Management 7,699,738 sh (-0.53%)
Jeff Ubben 7,163,892 sh (-15.49%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:BIVV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-06-30 Add 106.88%0.1%$51.9 - $62.57 $ 56.79-0%227,377
Ronald Muhlenkamp 2017-06-30 Reduce -0.10%$51.9 - $62.57 $ 56.79-0%11,531
First Eagle Investment 2017-06-30 Sold Out 0.02%$51.9 - $62.57 $ 56.79-0%0
First Eagle Investment 2017-03-31 Add 22.19%$41.82 - $54.46 $ 56.7918%157,035
Joel Greenblatt 2017-03-31 Reduce -8.53%0.01%$41.82 - $54.46 $ 56.7918%109,907
Ronald Muhlenkamp 2017-03-31 Reduce -0.83%$41.82 - $54.46 $ 56.7918%11,543
Vanguard Health Care Fund 2017-03-31 Sold Out $41.82 - $54.46 $ 56.7918%0
John Paulson 2017-03-31 Sold Out 0.01%$41.82 - $54.46 $ 56.7918%0
Ron Baron 2017-03-31 Sold Out $41.82 - $54.46 $ 56.7918%0
David Dreman 2017-03-31 Sold Out 0.01%$41.82 - $54.46 $ 56.7918%0
HOTCHKIS & WILEY 2017-03-31 Sold Out 0.03%$41.82 - $54.46 $ 56.7918%0
Mario Gabelli 2017-03-31 Sold Out $41.82 - $54.46 $ 56.7918%0
Ken Fisher 2017-03-31 Sold Out $41.82 - $54.46 $ 56.7918%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BLUE, NAS:TSRO, NAS:UTHR, NAS:NBIX, NAS:ALNY, NAS:JUNO, NAS:IONS, NAS:TECH, NAS:ACAD, NAS:SGEN, NAS:EXEL, NAS:PBYI, NAS:FGEN, NAS:NKTR, NAS:CLVS, NAS:AGIO, NAS:PTLA, NAS:ONCE, NAS:SRPT, NAS:LGND » details
Traded in other countries:50B.Germany, BIVV.Mexico,
Headquarter Location:USA
Bioverativ Inc is a global biotechnology company which focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders.

Bioverativ Inc is a global biotechnology company based in the US. It focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. The company market two products, ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein] and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B respectively. The company operates its business in one operating segment, which is Discovering, researching, developing and commercializing innovative therapies for the treatment of hemophilia and other blood disorders.

Ratios

vs
industry
vs
history
PE Ratio 13.52
BIVV's PE Ratio is ranked higher than
73% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. BIVV: 13.52 )
Ranked among companies with meaningful PE Ratio only.
BIVV' s PE Ratio Range Over the Past 10 Years
Min: 12.1  Med: 13.83 Max: 15.05
Current: 13.52
12.1
15.05
Forward PE Ratio 18.69
BIVV's Forward PE Ratio is ranked lower than
55% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. BIVV: 18.69 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 13.52
BIVV's PE Ratio without NRI is ranked higher than
74% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. BIVV: 13.52 )
Ranked among companies with meaningful PE Ratio without NRI only.
BIVV' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.1  Med: 13.83 Max: 15.05
Current: 13.52
12.1
15.05
PB Ratio 9.13
BIVV's PB Ratio is ranked lower than
85% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. BIVV: 9.13 )
Ranked among companies with meaningful PB Ratio only.
BIVV' s PB Ratio Range Over the Past 10 Years
Min: 8.86  Med: 9.7 Max: 10.87
Current: 9.13
8.86
10.87
PS Ratio 5.97
BIVV's PS Ratio is ranked higher than
63% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. BIVV: 5.97 )
Ranked among companies with meaningful PS Ratio only.
BIVV' s PS Ratio Range Over the Past 10 Years
Min: 5.62  Med: 6.2 Max: 6.7
Current: 5.97
5.62
6.7
Price-to-Free-Cash-Flow 16.78
BIVV's Price-to-Free-Cash-Flow is ranked higher than
62% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. BIVV: 16.78 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BIVV' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 16.26  Med: 17.91 Max: 20.08
Current: 16.78
16.26
20.08
Price-to-Operating-Cash-Flow 16.04
BIVV's Price-to-Operating-Cash-Flow is ranked higher than
64% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. BIVV: 16.04 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BIVV' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 14.93  Med: 16.58 Max: 17.84
Current: 16.04
14.93
17.84
EV-to-EBIT 15.59
BIVV's EV-to-EBIT is ranked higher than
57% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. BIVV: 15.59 )
Ranked among companies with meaningful EV-to-EBIT only.
BIVV' s EV-to-EBIT Range Over the Past 10 Years
Min: 14.7  Med: 16.4 Max: 17.7
Current: 15.59
14.7
17.7
EV-to-EBITDA 14.15
BIVV's EV-to-EBITDA is ranked higher than
56% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. BIVV: 14.15 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIVV' s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.7  Med: 14.5 Max: 15.8
Current: 14.15
12.7
15.8
EV-to-Revenue 5.85
BIVV's EV-to-Revenue is ranked higher than
66% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. BIVV: 5.85 )
Ranked among companies with meaningful EV-to-Revenue only.
BIVV' s EV-to-Revenue Range Over the Past 10 Years
Min: 5.2  Med: 6 Max: 6.5
Current: 5.85
5.2
6.5
Current Ratio 2.02
BIVV's Current Ratio is ranked higher than
55% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. BIVV: 2.02 )
Ranked among companies with meaningful Current Ratio only.
BIVV' s Current Ratio Range Over the Past 10 Years
Min: 2.02  Med: 4.66 Max: 5.82
Current: 2.02
2.02
5.82
Quick Ratio 1.81
BIVV's Quick Ratio is ranked higher than
54% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. BIVV: 1.81 )
Ranked among companies with meaningful Quick Ratio only.
BIVV' s Quick Ratio Range Over the Past 10 Years
Min: 1.06  Med: 1.69 Max: 4.24
Current: 1.81
1.06
4.24
Days Inventory 253.77
BIVV's Days Inventory is ranked lower than
82% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. BIVV: 253.77 )
Ranked among companies with meaningful Days Inventory only.
BIVV' s Days Inventory Range Over the Past 10 Years
Min: 253.77  Med: 943 Max: 1488.29
Current: 253.77
253.77
1488.29
Days Sales Outstanding 63.21
BIVV's Days Sales Outstanding is ranked higher than
59% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. BIVV: 63.21 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIVV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.45  Med: 61.5 Max: 183.04
Current: 63.21
61.45
183.04
Days Payable 21.57
BIVV's Days Payable is ranked lower than
77% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. BIVV: 21.57 )
Ranked among companies with meaningful Days Payable only.
BIVV' s Days Payable Range Over the Past 10 Years
Min: 19.49  Med: 74.52 Max: 143.05
Current: 21.57
19.49
143.05

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.96
BIVV's Price-to-Median-PS-Value is ranked lower than
58% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. BIVV: 0.96 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BIVV' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.93  Med: 1.01 Max: 1.02
Current: 0.96
0.93
1.02
Earnings Yield (Greenblatt) % 6.44
BIVV's Earnings Yield (Greenblatt) % is ranked higher than
89% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. BIVV: 6.44 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BIVV' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 5.6  Med: 6.1 Max: 6.8
Current: 6.44
5.6
6.8

More Statistics

Revenue (TTM) (Mil) $1,033.60
EPS (TTM) $ 4.20
Short Percentage of Float4.91%
52-Week Range $40.99 - 64.41
Shares Outstanding (Mil)108.18

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 861 976 922 965
EPS ($) 2.24 2.43 2.31 2.47
EPS without NRI ($) 2.24 2.43 2.31 2.47
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.99%
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}